Tuberculosis

BMJ

Volumn 316, Issue 7149, 1998, Pages 1962-

  Zumla, Alimuddin ^a   Grange, John ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

BCG VACCINE; TUBERCULOSTATIC AGENT; ISONIAZID; RIFAMPICIN;

ANTIBIOTIC RESISTANCE; HUMAN; IMMUNOLOGY; INNATE IMMUNITY; REVIEW; TUBERCULOSIS; MEDICAL RESEARCH; PRIORITY JOURNAL; SHORT SURVEY; TUBERCULOSIS CONTROL;

ANTITUBERCULAR AGENTS; BCG VACCINE; DRUG RESISTANCE, MICROBIAL; HUMANS; IMMUNITY, NATURAL; TUBERCULOSIS;

EID: 0032572182     PISSN: 09598138     EISSN: 14685833     Source Type: Journal    
DOI: 10.1136/bmj.316.7149.1962     Document Type: Article

References (18)

1. World Health Organisation. TB a global emergency. WHO report on the TB epidemic. Geneva: WHO, 1994.
2. Zumla A Grange J. Establishing a united front against the injustice of tuberculosis. Int J Tuberc Lung Dis 1998; 3: 1–4.
3. World Health Organisation. The world health report 1998. Geneva: WHO, 1998.
4. Raviglione M Nunn P.P. Epidemiology of tuberculosis. In: Ed. Zumla A. Johnson M. Miller R.F., eds. AIDS and respiratory medicine., London: Chapman and Hall, 1997:117–143.
5. World Health Organisation. Anti-tuberculosis drug resistance in the world. The WHO/IUATLD global project on anti-tuberculosis drug resistance surveillance. Geneva: WHO, 1997.
6. Butcher P.D. Hutchinson N.A. Doran T.J. Dale J.W. The application of molecular techniques to the diagnosis and epidemiology of mycobacterial diseases. J Appl Bacteriol 1996; 81(suppl): 53–71S.
7. Doucet-Populaire F. Lalande V. Carpentier E. Bourgoin A. Dailloux M. Bollet A. et al. A blind study of the polymerase chain reaction for the detection of Mycobacterium tuberculosis DNA. Tuber Lung Dis 1996; 77: 358–362.
8. Van Embden J.D.A. Cave M.D. Crawford J.T. Strain identification of Mycobacterium tuberculosis by DNA fingerprinting: recommendations for a standardised methodology. J Clin Microbiol 1993; 31: 406–409.
9. Falkinham J.O., ed. Solving the dilemma of antimycobacterial chemotherapy. Res Microbiol 1996; 147: 7–121.
10. Fine P.E.M. Variation in protection by BCG: implications of and for heterologous immunity. Lancet 1995; 346: 1339–1345.
11. Department of Health. Immunisation against infectious disease 1996 edition., London: HMSO, 1996:219–241.
12. Young D.B. Tuberculosis: prospects for new vaccines. Biotechnology and world health: risks and benefits of vaccines and other medical products produced by genetic engineering., Geneva: World Health Organisation, 1997:35–38. (WHOBLG/97.01.)
13. Rook G.A.W. Baker R. Nakhli S. Zumla A. Endocrine regulation of T lymphocyte subpopulations. In: Ed. KumberISelgardeM, eds. T lymphocyte regulation in immunotoxicology., London: J Wiley, 1998:179–198.
14. Hernandez-Pando R. Rook G.A.W. The role of TNF in T cell-mediated inflammation depends on the Th1/Th2 cytokine balance. Immunology 1994; 82: 591–595.
15. Rook G.A.W. Steele J. Ainsworth M. Leveton C.A. A direct effect of glucocorticoid hormones on the ability of human and murine macrophages to control the growth of M. tuberculosis. Eur J Respir Dis 1987; 71: 286–291.
16. Grange J.M. Stanford J.L. Therapeutic vaccines. J Med Microbiol 1996; 45: 81–83.
17. Grange J Zumla A. Making DOTS (directly observed therapy for tuberculosis) work. Lancet 1997; 350: 157.
18. Department for International Development. Eliminating world poverty: a challenge for the 21st century. UK government white paper, November, 1997. London: Stationery Office, 1997.